Supporting Experimental Procedures
Indirect immunofluorescence analysis
Indirect immunofluorescence analysis was performed essentially as described previously (16). Briefly, after fixation with 4% paraformaldehyde and permeabilization with 0.3% Triton X-100, an anti-HBc antibody (DAKO, #B0586) was used as the primary antibody.
ELISA
To quantify HBs protein by ELISA, microwell antigen capture plates (Maxisorp nunc-immuno plate, Nunc #439454) were prepared by overnight incubation at 4˚C with a sheep anti-HBs antibody at 1:5000 dilution, followed by coating with 0.2% BSA/0.02% NaN 3 /1 x PBS at 4˚C until use. For HBs detection, samples were incubated in individual wells of the capture plates for 2 h. After washing, horseradish peroxidase-labeled rabbit anti-HBs antibody was added for an additional 2 h incubation. The substrate solution (from the HCV core ELISA kit: Ortho) was reacted for 15-60 min before the OD 450 values were measured.
Real time PCR and RT-PCR
HBV DNA was extracted from cells using a QIAamp mini kit (QIAGEN) according to the manufacturer's protocol. HBV DNA was quantified by real time PCR analysis using the primer set 5'-ACTCACCAACCTCCTGTCCT-3' and 5'-GACAAACGGGCAACATACCT-3' and probe 5'FAM-TATCGCTGGATGTGTCTGCGGCGT-TAMRA3'.
Detection of cccDNA was achieved using 5'-CGTCTGTGCCTTCTCATCTGC-3' and 5'-GCACAGCTTGGAGGCTTGAA-3' as primers and 5'-CTGTAGGCATAAATTGGT (MGB)-3' as a probe. mRNAs for NTCP, CyPA, CyPB, and GAPDH were detected using a one step RNA PCR kit (Takara) following the manufacturer's protocol. Primers are 
Southern blot analysis
Southern blotting was performed as described previously (23).
HBV attachment and internalization assay
To allow HBV attachment to the cells without subsequent internalization, HBV was added to HepaRG cells at 4˚C for 3 h. Free HBV was removed by washing the cells with PBS. 
Pretreatment of HBV particles with compounds
HBV inoculum, prepared as described above, was preincubated with the indicated compounds ( Fig. 2F) for 30 min at 37˚C. Each compound-treated HBV inoculum was concentrated from 450 ml to 15 ul via ultrafiltration, followed by dilution to 450 ml with PBS and re-concentration to recover 15 ul of HBV-containing medium. This procedure is expected to result in a 900-fold reduction in compound concentration. The infectivity of the resultant HBV-containing concentrate (10 ml) was evaluated by inoculating HepaRG cells as described above.
MTT assay
The MTT cell viability assay was performed as described previously (23).
Reporter assay
Gene expression reporter assays were performed essentially as described (18). Briefly, the 
HCV pseudoparticle assay
The HCV pseudoparticle (HCVpp) assay was essentially performed as previously described (55, 56) . Plasmids used to produce HCVpp, were kindly provided by Dr. Francois-Loic
Cosset at University of Lyon.
Cyclophilin binding assay
Binding For the HepG2-based transporter assay in Fig. 5B , the uptake experiments were performed as described (59, 60) by using HepG2 and HepG2-NTCP with modification. The uptake of from HepG2-NTCP uptake value.
Binding assay for CsA to NTCP-containing membranes
Crude membrane fractions of HepG2 and HepG2-NTCP cells were prepared as described (60) . For the binding assay, 42.5 mg of crude membrane fraction was mixed with 100 ml of 30 mM 
AlphaScreen assay for NTCP-HBs binding
Recombinant NTCP and HBs proteins were synthesized using a wheat cell-free protein system as described previously (63) (64) (65) . The template for transcription was produced by split-primer PCR using the following primers: a target protein specific primer (5'- 
Statistical analyses
Statistical significance was determined using the Student's t-test.
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Activity PEG8000 using the protocol shown in Fig. 1A . 
